TAMPA, Fla., USA — Valcare Medical, Inc., a pioneer in transcatheter mitral valve solutions, unveiled a significant corporate restructuring led by Techwald Next. This strategic move is set to boost the initiation of the AMEND mitral annuloplasty clinical studies in Europe and the United States.
Strategic Leadership and Restructure
As a part of this restructure, Steve Sandweg has been appointed as the new Chief Executive Officer of Valcare Medical. Sandweg, with a 25-year tenure in the medical device industry, brings extensive experience from his previous roles at EBR Systems, Inc, Keystone Heart, Direct Flow Medical, and Medtronic Corp. His background is rich in leading commercial and clinical operations, particularly in the cardiovascular and structural heart arenas.
“I’m excited and honored to be joining such a remarkably talented team,” said Sandweg. “The corporate restructure offers a unique opportunity for us to increase focus and accelerate performance. Following the success of our first in human experience in which 33 patients were treated with AMEND and showed promising results, we are eager to now begin enrolling patients in the AMEND Plus European pilot study and continuing our work with the FDA on a future IDE submission.”
Enhanced Board Leadership
Alongside CEO Steve Sandweg, Chris Richardson has been named Executive Board Chair. Richardson’s vast experience in the medical device sector, including leading Keystone Heart through its acquisition by Venus Medtech, positions him well to steer Valcare through its next phases of development.
“We’re fortunate to have Steve come on board at this important stage in Valcare’s development,” Richardson noted. “Steve has the experience and operational track record the company needs at this time to execute on its ambitious plan to transform the standard of care for patients suffering from severe mitral regurgitation.”
About Valcare Medical
Valcare Medical specializes in minimally invasive technologies for the treatment of mitral and tricuspid valve regurgitation. The company’s innovative AMEND mitral valve repair device, currently limited to investigational use, exemplifies its pioneering approach to cardiac care. This device, along with future mitral replacement and tricuspid repair solutions, showcases Valcare’s commitment to advancing cardiac treatment through breakthrough technologies.
Also Read : Listening Leaders: The Key to Unlocking Team Potential
